Fast Moving Stocks: Capital Product Partners L.P. (NASDAQ:CPLP), Celgene Corporation (NASDAQ:CELG), First American Financial Corporation (NYSE:FAF), Concert Pharmaceuticals (NASDAQ:CNCE), IGI Laboratories (NYSEMKT:IG)

Capital Product Partners L.P. (NASDAQ:CPLP) belongs to Services sector. Its net profit margin is 16.20% and weekly performance is 0.64%. On last trading day company shares ended up $7.84. Capital Product Partners L.P. (NASDAQ:CPLP) distance from 50-day simple moving average (SMA50) is -8.13%. On 1st July, Capital Product Partners L.P. (NASDAQ: CPLP) announced the successful acquisition of the M/T ‘Amadeus’.

Celgene Corporation (NASDAQ:CELG) shares moved up 1.69% in last trading session and ended the day at $118.84. CELG Gross Margin is 95.00% and its return on assets is 14.60%. Celgene Corporation (NASDAQ:CELG) quarterly performance is 1.51%. Celgene Corporation (NASDAQ:CELG) will host a conference call and live audio webcast on Thursday, July 23, 2015 at 9 a.m. ET to discuss second quarter 2015 financial and operational results.

On 10 July, First American Financial Corporation (NYSE:FAF) shares moved up 3.70% and was closed at $39.53. FAF EPS growth in last 5 year was 12.60%. First American Financial Corporation (NYSE:FAF) year to date (YTD) performance is 18.28%. First American Financial Corporation (NYSE:FAF), announced that it will host a conference call on Thursday, July 23, 2015, at 11 a.m. EDT.

Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) ended the last trading day at $15.71. Company weekly volatility is calculated as 4.13% and price to cash ratio as 3.02. Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) showed a weekly performance of 5.65%. Concert Pharmaceuticals (NASDAQ:CNCE) had its target price lifted by Ladenburg Thalmann from $24.00 to $27.00 in a research note released on Wednesday morning. They currently have a buy rating on the stock.

IGI Laboratories, Inc. (NYSEMKT:IG) shares advanced 3.24% in last trading session and ended the day at $6.69. IG Gross Margin is 52.10% and its return on assets is 10.20%. IGI Laboratories, Inc. (NYSEMKT:IG) quarterly performance is -18.71%. IGI Laboratories, Inc. (NYSE MKT: IG), announced it has launched its seventh product, diclofenac sodium 1.5% topical solution, after receipt of the final approval from the U.S. Food and Drug Administration (FDA) for an abbreviated new drug application (ANDA). The Company now markets seven products in twelve presentations in an IGI label.

Leave a Reply

Your email address will not be published. Required fields are marked *